NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery comp ...

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, ...

Zimbabwe's health authorities began administering the long-acting HIV prevention drug lenacapavir, making the country one of the first globally to roll it out as the southern African nation seeks to ...

U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) said on Friday that the U.S. Food and Drug Administration (FDA) ...

An ongoing phase 2 trial (NCT07222579) has seen early success with a new subcutaneous formulation of blinatumomab (Blincyto) in a patient with CD19-positive mixed phenotype acute leukemia (MPAL), a ...

Zimbabwe's health authorities on Thursday began administering the long-acting HIV prevention drug lenacapavir, making the ...

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

The agency last December approved subcutaneous Rybrevant on a biweekly dosing schedule across all of its indications.

The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment ...

Monash University researchers alongside key partner Halozyme Therapeutics have reported findings in support of shifting the way anti-cancer immunotherapy is administered from intravenous ...